Penicillin Resistance of Nonvaccine Type Pneumococcus before and after PCV13 Introduction, United States

Emerg Infect Dis. 2017 Jun;23(6):1012-1015. doi: 10.3201/eid2306.161331.

Abstract

Introduction of 13-valent pneumococcal conjugate vaccine in the United States was not associated with a significant change in prevalence of penicillin resistance in nonvaccine type serotypes because of the variable success of highly resistant serotypes. Differences in regional serotype distribution and serotype-specific resistance contributed to geographic heterogeneity of penicillin resistance.

Keywords: 13-valent pneumococcal conjugate vaccine; PCV13; Streptococcus pneumoniae; United States; antibiotic resistance; antimicrobial resistance; bacteria; bacterial infection; geographic variation; nonvaccine type; penicillin; pneumococcus; serotype; temporal variation; vaccines.

Publication types

  • Multicenter Study

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Carrier State
  • Cross-Sectional Studies
  • Humans
  • Mass Vaccination
  • Microbial Sensitivity Tests
  • Penicillin Resistance*
  • Penicillins / pharmacology*
  • Pneumococcal Infections / drug therapy
  • Pneumococcal Infections / epidemiology*
  • Pneumococcal Infections / immunology
  • Pneumococcal Infections / prevention & control
  • Pneumococcal Vaccines / administration & dosage*
  • Prevalence
  • Serogroup
  • Serotyping
  • Streptococcus pneumoniae / classification
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / genetics
  • Streptococcus pneumoniae / immunology
  • United States / epidemiology
  • Vaccines, Conjugate

Substances

  • 13-valent pneumococcal vaccine
  • Anti-Bacterial Agents
  • Penicillins
  • Pneumococcal Vaccines
  • Vaccines, Conjugate